Trial Profile
A Planned Phase III Trial of Neratinib Plus Temsirolimus for Patients With Metastatic HER2-Breast Cancer.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2015
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Temsirolimus
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Sponsors Puma Biotechnology
- 02 Mar 2015 According to Puma Biotechnology, Inc. media release, company is planning to initiate this trial in the second half of 2015.
- 02 Mar 2015 Planned initiation date changed from 1 Dec 2014 to 1 Jul 2015, as reported by Puma Biotechnology, Inc. media release.
- 13 Nov 2013 Planned initiation date changed from 1 Dec 2013 to 1 Jun 2014.